Abstract | BACKGROUND/AIMS: METHODS: From 7 tertiary referral hospitals, 33 patients who were treated with infliximab for moderate to severe (Mayo score 6-12) UC refractory to conventional treatment were recruited to this study. Clinical remission was defined as a total Mayo score of 2 or lower and every subscore less than 2. Partial response was defined as a decrease of Mayo score at least 3 points from baseline. RESULTS: Twenty-three patients (69.7%) showed clinical remission and 29 patients (87.8%) showed partial response in the observation period. When the remission and non-remission groups were compared in univariate analysis, only a higher total Mayo score at base line (11.0±0.9 vs. 9.9±1.5; P=0.04) was related to remission. The remission maintenance rate decreased with time in the Kaplan-Meier analysis. Two patients experienced re-remission after the first remission followed by aggravation during infliximab treatment. Three patients stopped infliximab treatment owing to adverse events including rhabdomyolysis, pneumonia, and fever of unknown origin. CONCLUSIONS: If there is no choice except surgery for UC patients refractory to conventional treatment, infliximab is an effective and relatively safe treatment option for these patients in Korea.
|
Authors | Hyun Il Seo, Dong Il Park, Tae Oh Kim, You Sun Kim, Suck-Ho Lee, Ji Won Kim, Jae Hak Kim, Jeong Eun Shin |
Journal | Intestinal research
(Intest Res)
Vol. 12
Issue 3
Pg. 214-20
(Jul 2014)
ISSN: 1598-9100 [Print] Korea (South) |
PMID | 25349595
(Publication Type: Journal Article)
|